Capricor Therapeutics, Inc. (CAPR)
NASDAQ: CAPR · Real-Time Price · USD
26.89
+1.49 (5.87%)
At close: Dec 5, 2025, 4:00 PM EST
26.88
-0.01 (-0.04%)
After-hours: Dec 5, 2025, 7:59 PM EST
Capricor Therapeutics Employees
Capricor Therapeutics had 160 employees as of December 31, 2024. The number of employees increased by 58 or 56.86% compared to the previous year.
Employees
160
Change (1Y)
58
Growth (1Y)
56.86%
Revenue / Employee
$69,566
Profits / Employee
-$512,435
Market Cap
1.23B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CAPR News
- 11 hours ago - Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Top Line Data for Deramiocel in Duchenne Muscular Dystrophy Transcript - Seeking Alpha
- 1 day ago - Capricor Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 2 days ago - Capricor Stock Soars, Shkreli Is Short: Here's What Pharma Bro Had To Say - Benzinga
- 3 days ago - Capricor Therapeutics Duchenne Treatment Shows Strong Heart And Muscle Results In Trial - Benzinga
- 3 days ago - Capricor's muscle disorder cell therapy succeeds in late-stage study - Reuters
- 11 days ago - Martin Shkreli Takes Aim At Capricor — Stock Sinks - Benzinga
- 25 days ago - Capricor Therapeutics, Inc. (CAPR) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel - GlobeNewsWire